The Powerhouse for Anti-infectives Committed to making the difference Read more AiCuris is a pharmaceutical company specializing in the discovery, research and development of novel, resistance‐breaking antiviral and antibacterial agents for the treatment of serious and potentially life-threatening infectious diseases. Founded in 2006 as a spin‐out from Bayer Infection Research, AiCuris today manages an innovative pipeline of anti-infective agents with a team of internationally recognized scientists in Research and Development. We are one of the few European biotech companies which has brought a drug with “blockbuster” potential to the market (Prevymis® 2017/18). LATEST NEWS 2021-11-16 EBMT Transplant Complications Working Party Educational Meeting (virtual) 19 Nov 2021 Listen to the talks of Dr. Alexander Birkmann, AiCuris and Prof. Margeret Kingston, Manchester University NHS Foundation Trust discussing the burden of HSV infections in immunocompromised patients and the need for novel approaches to address foscarnet as well as acyclovir- & foscarnet-resistance. Read more 2021-10-22 AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, today announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin®-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections. Read more ABOUT US Fighting infectious diseases of the 21st century AiCuris was created in 2006 as a spin-out of Bayer’s anti-infective division and is backed by the Strüngmann family office as lead investor and other private investors well known in Germany. We develop innovative drugs against severe and life-threatening infectious diseases. By targeting indications with high medical need, as well as preparing for pandemic and resistance emergencies, we focus on markets where no efficient solution is available and bring novel approaches into a long-underserved sector. Read more RESEARCH & DEVELOPMENT Our innovative Pipeline Innovative therapies demand extraordinary means. With an international team of renowned scientists, proven competence in clinical development, and a global network of experts and reliable partners, we differentiate our pipeline by using an indication-driven, technology-agnostic approach. Read more PARTNERING & COLLABORATIONS Expanding our Portfolio AiCuris is constantly evaluating strategic partnerships and collaboration opportunities with biotech or pharmaceutical companies. In addition, we are always interested in new collaborations with innovative, science-driven organizations and academic institutions to develop the next resistance-breaking antibiotic or anti-infective. Read more If you or your company are interested in partnering with AiCuris, please contact us. Contact Imprint·Privacy Notice·Tools & Services·EFPIA Disclosure Code © AiCuris Anti-infective Cures AG realized by cekom GmbH